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ABSTRACT 
 
The innate immune pathways that stimulate the expression of cytokines and 
proapoptotic factors in response to infection are triggered by the activation of the 
cytosolic receptors retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-
associated gene 5 (MDA5). Activation of both receptors occurs as a result of binding to 
RNA. MDA5 only recognizes double stranded forms of RNA, whereas RIG-I is capable 
of recognizing both single and double stranded RNA. In vivo, MDA5 is known to be 
stimulated by long (>1 kb) strands of RNA, forming filaments along the phosphate 
backbone. However, the manner in which MDA5 can recognize the terminal end of its 
RNA ligand is uncertain. 
I have examined the mechanism of binding of the MDA5 protein by comparing 
MDA5 binding to short (<18 bp) blunt RNA, 5’ triphosphate RNA, and RNA with a 3’ 
or 5’ overhang. It is shown that while the MDA5 protein regulatory domain (RD) is 
essential for RNA recognition, the MDA5 RD only weakly recognizes short double 
stranded RNA ligands with overhangs or a 5’ triphosphate group. The Cys951 residue 
was shown to disrupt stability of the MDA5 RD-RNA complex. Binding analyses were 
performed using a combination of SDS-PAGE, gel filtration analysis, and non-
denaturing gel electrophoresis. In addition, structural data was gathered by 
crystallization of the MDA5 RD-RNA complex using X-ray crystallography. These 
results help to establish the manner in which MDA5 is regulated predominantly to the 
binding of long RNA ligands. 
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Also included in this document is structural data on the dimer form of the PepQ 
protein from E. coli. PepQ is a highly conserved proline peptidase that has a secondary 
activity of hydrolyzing organophosphorus triesters, toxic compounds found in many 
pesticides. The PepQ protein was crystallized and analyzed by X-ray diffraction. The 
dimer interface was clearly defined within the structure and provides insight into how 
the active dimer forms from the PepQ monomer. 
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NOMENCLATURE 
 
AMP-PNP adenosine 5′-(β,γ-imido) triphosphate 
CARD caspase activation and recruitment domain 
CIP calf intestinal phosphotase 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
dGTP deoxyguanosine triphosphate 
DNA dideoxyribonucleic acid 
dsRNA double-stranded RNA 
DTT dithiothreitol 
dTTP deoxythymidine triphosphate 
EMSA electromobility shift assay 
HD helicase domain 
IPTG isopropyl β-D-1-thiogalactopyranoside 
IVT in vitro transcription 
LB Luria-Bertani (growth media) 
LGP2 Laboratory of Genetics and Physiology 2 
MDA5 melanoma differentiation-associated gene 5 
MME monomethyl ether 
MPD (+/-)-2-methyl-2,4-pentanediol 
MR molecular replacement 
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PCR polymerase chain reaction 
PEG polyethylene glycol 
PMSF phenylmethanesulfonylfluoride 
RD regulatory domain 
RIG-I retinoic acid-inducible gene I 
RNA ribonucleic acid 
SAD single wavelength anomalous diffraction 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC size exclusion or gel filtration chromatography 
ssRNA single-stranded RNA 
SUMO small ubiquitin-like modifier 
TEMED tetramethylethylenediamine 
Tris tris(hydroxymethyl)aminomethane 
WT wild type 
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CHAPTER I 
INTRODUCTION 
 
MDA5 is an essential protein of the innate immunity pathway and serves as a 
cytosolic receptor for foreign dsRNA within the cell. Its activation triggers a series of 
signaling pathways that culminate in both apoptosis and the release of cytokines. The 
mechanism of how the MDA5 protein of H. sapiens recognizes dsRNA at its 5’ end is of 
interest. Knowledge of the binding mechanism of MDA5 would serve to elucidate the 
effects certain mutations would have on MDA5’s function, and help to suggest potential 
treatments to alleviate these effects. 
The proline peptidase PepQ of E. coli is also of interest. While its primary 
function of hydrolyzing the backbone of Xaa-Pro dipeptides is significant, its secondary 
function of hydrolyzing organophosphorous toxins makes it a potential subject of 
research in biochemical waste cleanup. Here the crystal structure of the biochemically 
active PepQ dimer has been determined and introductory structural analysis has been 
performed. This paper will serve to present the cumulative experimental data collected 
on the mechanisms of H. sapiens MDA5 binding to dsRNA and on the crystal structure 
of E. coli PepQ.  
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CHAPTER II 
RECOGNITION AND BINDING MECHANISM OF H. sapiens MDA5 WITH 
FOREIGN DOUBLE-STRANDED RNA 
 
Introduction 
During viral and bacterial infection of a cell, the first line of defense comes from 
the innate immune pathways. These pathways are triggered by the activation of receptors 
through the recognition of pathogen associated molecular patterns (PAMPs). PAMPs are 
unique molecules that emerge during infection, such as foreign proteins or nucleic acids. 
[1] Examples of receptors that bind to PAMPs include AIM2 (absent in melanoma 2), 
which recognizes cytosolic dsDNA, NAIP5 (NOD-like receptor family, apoptosis 
inhibitory protein 5), which recognizes the bacterial protein flagellin, and STING 
(stimulator of interferon genes), which recognizes bacterial cyclic dinucleotides. [2-4] 
MDA5 is a member of the RIG-I-like receptor (RLR) family of proteins, a set of PAMP 
receptors that respond to cytosolic RNA. [5] 
RLRs include RIG-I (retinoic acid inducible gene I), MDA5, and LGP2 
(Laboratory of Genetics and Physiology 2). These proteins are found in most vertebrate 
tissues and are localized in the cytosol. They recognize the presence of cytosolic viral 
RNA through their C-terminal regulatory binding domains. When activated, RIG-I and 
MDA5 stimulate the mitochondrial-bound IPS-1 (also known as MAVS/Cardif/VISA). 
The LGP2 protein in turn has been determined to act in a positive regulatory role for 
RIG-I and MDA5 signaling of IPS-1. [6] Once activated, IPS-1 triggers an innate 
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immune response through signaling pathways to phosphorylate and activate IRF 
(interferon regulatory factors) 3 and 7, and to activate NF-κB (nuclear factor kappa B). 
These pathways result in the expression of type-I interferon and proinflammatory 
cytokines, which assist in the cellular defense against cytolytic viruses like hepatitis C. 
[7] Pro-apoptotic pathways are also stimulated, helping to further arrest the progress of 
an active infection in the organism. [8] 
Each of the RLR family of proteins contains a C-terminal regulatory domain 
(RD) that binds to RNA and a helicase domain (HD) that is capable of RNA-dependent 
ATP hydrolysis. The proteins RIG-I and MDA5 also each contain an N-terminal caspase 
activation and recruitment domain (CARD). [5] Upon binding to an RNA ligand, RIG-I 
and MDA5 CARDs become available for signaling and directly stimulate the innate 
immune pathway through a CARD-CARD interaction with IPS-1. [9, 10] 
The RLR proteins have different structural specificities for viral RNA. RIG-I and 
LGP2 can recognize both single-stranded (ssRNA) and double-stranded RNA (dsRNA), 
while MDA5 recognizes only dsRNA. [11] Another aspect of MDA5 is that recognition 
of the dsRNA is not done by a single protein binding to the RNA terminus, but by a 
stacking series of MDA5 monomers that form a filament along the length of the RNA. 
[12] Structural studies of these proteins have helped to elucidate these mechanisms of 
RIG-I binding to the RNA terminus, and of MDA5 binding along the RNA phosphate 
backbone. However, preliminary studies of MDA5 with dsRNA oligos of less than 16 bp 
in length showed that MDA5 binds dsRNA in a 2:1 ratio. The binding was also 
influenced by the composition of the RNA terminus. This implies that MDA5 can bind 
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and recognize short RNA ligands in an alternate manner. Here I will focus on the 
interaction of MDA5 with the terminus of short dsRNA. 
Recently, the structures of ΔCARD RIG-I and ΔCARD MDA5 bound to dsRNA 
(4AY2, 4GL2) have been solved. [10, 13]  The structure of the RIG-I RD with dsRNA 
(3LRN, 3LRR) has also been solved. [14] This allows for comparison of the orientation 
of RNA during the initial binding to the RIG-I RD the final active complex of RIG-I and 
dsRNA. The structure of the MDA5 RD with dsRNA has not been solved, however. This 
information would help to establish how the MDA5 RD is involved with the initiation of 
RNA binding prior to the formation of the MDA5-RNA filament-like complex. 
 
Objective 
The manner in which MDA5 recognizes dsRNA in the cytosol is important as 
activated MDA5 signals an innate immune response pathway that eventually results in 
the expression and secretion of cytokines and the stimulation of apoptosis. Structural 
knowledge of MDA5 in complex with dsRNA at the point of initial interaction with 
RNA would be essential. This information would help to elucidate the role of MDA5 in 
the activation of the innate immune system in contrast with its related family members, 
RIG-I and LGP2. Additional studies into the stoichiometry and binding mechanism of 
this complex would help to further support the current research into this protein. To 
characterize these aspects, the following specific aims were performed. 
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Specific Aims 
Specific aim 1: MDA5 construct expression and purification 
The HD-only, RD-only, and HDRD (ΔCARD; HD and RD only) truncations of 
MDA5 were expressed in E. coli. The full length MDA5 protein was shown to be 
insoluble and could not be purified successfully from E. coli. A vector including a 
SUMO tag was used to improve solubility of the HD and HDRD proteins. The RD of 
MDA5 is essential for initial RNA binding, while the HD is involved in the subsequent 
conformational change to the RNA-bound active form. 
 
Specific aim 2: Stoichiometry and stability of the MDA5 and dsRNA complex 
Binding analyses of the MDA5/dsRNA complex were performed using both size 
exclusion chromatography (SEC) and electromobility shift assays (EMSAs). The RD, 
HD, and HDRD constructs of MDA5 were used. The MDA5 full length protein has a 16-
18 bp footprint when bound to dsRNA [12], so dsRNA lengths were limited to less than 
18 bp. This information helped establish the stoichiometry and stability of the complexes 
formed from these constructs. 
 
Specific aim 3: Mechanism of the MDA5-dsRNA interaction 
Mutagenesis and truncations were used to help improve the stability of the 
MDA5-dsRNA complex and elucidate domains essential for the binding mechanism. 
Binding analyses by EMSA and SEC were performed with dsRNA to determine the 
influence of the RNA terminus on binding by MDA5. Crystallization and X-ray 
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diffraction experiments were performed to attempt to obtain a crystal structure of the 
MDA5 RD in complex with dsRNA. A crystal structure of this complex would help to 
reveal the mechanisms by which MDA5 initially recognizes foreign dsRNA in the cell 
prior to IPS-1 signaling. 
 
Experimental Procedures 
Design of MDA5 constructs for expression 
The full length (FL; 1-1025), regulatory domain (RD; residues 893-1017), 
helicase domain (HD; residues 301-889), helicase and regulatory domains (HDRD; 
residues 301-1025), HDRD with a C-terminal truncation (HDRDΔC; 301-1017), HDRD 
with a Hel2i-loop truncation (HDRDΔL; 301-645, 663-1025), and HDRD with both the 
Hel2i-loop and C-terminal truncations (HDRDΔCL; 301-645, 663-1017) were all 
selected for expression. The RD construct was provided by Dr. Pingwei Li in a 
pET22b(+) expression vector. The remaining construct designs were based upon a model 
of the MDA5 protein developed using the published RIG-I HD structure (PDB ID: 
4A2W; Fig. 1) [9] as a template and computationally generated by SWISS-Model. [15, 
16] When the MDA5 model was overlaid on the RIG-I structure, MDA5 corresponded 
to the RIG-I HD with few deviations (RMS = 0.081, Fig. 1). The Hel2i loop extension, 
not seen in the RIG-I structure, was modeled as a β-sheet. This modeling process was 
repeated using the RIG-I HDRD structure as a template (PDB ID: 2YKG). [17] 
However, while the MDA5 model again corresponded to the RIG-I structure (RMS = 
0.071), the Hel2i loop was modeled in this case as a disordered loop. Secondary 
structure predicition algorithms Heirarchical Neural Networks [18], JPred [19], and 
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PsiPRED [20, 21] were all used to predict secondary structure of MDA5 and this 
information was correlated to the MDA5 model to design the truncations. 
 
 
 
Fig. 1: MDA5 model overlaid on RIG-I structure (PDB ID: 4A2W). White - RIG-I 
HD stucture. Color - MDA5 model matching RIG-I structure. Gray - MDA5 loops not 
corresponding to the RIG-I structure. Arrow marks the gray Hel2i loop. 
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Cloning of MDA5 constructs 
Forward and reverse primers were designed with BamHI and NotI restriction 
sites, respectively, and ordered from Integrated DNA Technology (IDT). PCR was 
performed using Platinum Pfx DNA polymerase (Invitrogen, USA) with 1 μL of each 
primer (1 mg/ml), 40 ng of cDNA template plasmid, 2 μL of MgSO4 (50 mM), 5 μL of 
10x Pfx DNA polymerase amplification buffer, 5 μL of 10x Pfx DNA polymerase 
enhancer, 1 μL of dNTP (25 mM each of dATP, dCTP, dGTP, and dTTP) and diluted to 
a total volume of 50 μL by Milli-Q H2O. The mixture was heated to 95°C for 2 min, and 
then cycled 35 times at 95°C for 1 min. (denaturing step), 54°C for 1 min. (annealing 
step), and 68°C for 2-6 min. (extension step; 2 min per kb of construct, minimum 2 min). 
The reaction was finished by an additional extension at 68°C for 10 min. and then cooled 
at 4°C for 6 min. The template plasmid DNA was eliminated using 20 U of DpnI 
restriction enzyme (New England Biolabs, Inc., USA) at 37°C for 1 hr. The PCR product 
was verified by ethidium bromide-stained agarose gel and visualized by UV exposure. 
The product was then purified by the QIAquick PCR Purification Kit (Qiagen, 
Netherlands) and digested by 50 U of BamHI-HF and NotI restriction enzymes (New 
England Biolabs, Inc., USA) in a mixture containing 5 μL of 10x NEBuffer 4 and 5 μg 
bovine serum albumin, and diluted to a final volume of 50 μL by Milli-Q H2O. 1 mg of a 
modified pET28a vector containing a hexahistidine tag and a SUMO tag at the N-
terminus (pET28a-SUMO) was likewise digested, but using 100 U of each enzyme, 10 
μL of 10x restriction enzyme buffer, and a final volume of 100 μL by Milli-Q H2O. 
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The digested insert and vector fragments were purified by ethidium bromide-
stained agarose gel and QIAquick Gel Extraction Kits (Qiagen, Netherlands). Ligation 
was carried out using 1 U of T4 DNA ligase and 1 μL of 10x T4 DNA ligase buffer 
(Invitrogen, USA) at 22°C for 5 hr with 400 ng of insert DNA and 200 ng of vector 
DNA, and then diluted to a final volume of 10 μl. All MDA5 constructs, except for the 
MDA5 RD, were ligated to the pET28-SUMO expression vector. Ligation success was 
verified by DNA sequencing. The expression vectors containing the MDA5 constructs 
were used to transform Escherichia coli BL21 (DE3) heat-shock competent cells, which 
were then plated on Luria Bertani (LB) agar plates containing either 100 mg/L ampicillin 
or 50 mg/L kanamycin. A summary of the constructs and respective vectors is provided 
in Table 1. 
  
Table 1: MDA5 construct summary 
Construct Residue range MW† (kD) Expr. vector Antibiotic 
RD 301-1017 15.0 pET22b(+) Amp 
HD  301-889 67.7 pET28a-SUMO Kan 
HDRD  301-1025 83.5 pET28a-SUMO Kan 
HDRDΔL 301-645,663-1025 81.6 pET28a-SUMO Kan 
HDRDΔC 301-1017 82.6 pET28a-SUMO Kan 
HDRDΔCL 301-645,663-1017 80.7 pET28a-SUMO Kan 
  
Cysteine mutagenesis of the MDA5 RD 
Initial expression of the MDA5 RD was impeded by solubility issues with the 
protein. In addition, the protein construct formed a dimer during the purification process. 
It was hypothesized that the expressed protein formed a dimer which was mediated by a 
†Proteins expressed with pET28a-SUMO contain an N-terminal SUMO tag and are 15 kD larger 
than listed. The MW listed is for the construct without the SUMO tag. 
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surface disulfide bond, and that this dimer was prone to aggregation in solution. Site-
directed mutagenesis on the MDA5 RD construct was performed in order to mutate the 
surface cysteines Cys915 and Cys951 each to serine. A mixture was prepared of 2.5 U of 
PfuUltra High-fidelity DNA polymerase and 5 μL of PfuUltra reaction buffer 
(Invitrogen, USA), 25 nmol of dNTP (dATP, dCTP, dGTP, dTTP), 125 ng each of the 
forward and reverse primers (Table 2), and 50 ng of the template plasmid diluted with 
Milli-Q H2O to a final volume of 50 μL. The reaction mixture was heated at 95°C for 2 
min., and then cycled 16 times at 95°C for 30 sec (denaturing), 54°C for 1 min. 
(annealing), and then 68°C for 12 min. (extension). The reaction was completed with an 
additional extension time of 10 min. at 68°C followed by cooling at 4°C for 10 min. 
 
Table 2: Primers for MDA5 cysteine mutations 
C915S forward primer: 
5’-GCAAAAACTGCAGTGTGCTAGCCAGTTCTGGGGAAGATATCCATGTAATTG-3’ 
C915S reverse primer: 
5’-CAATTACATGGATATCTTCCCCAGAACTGGCTAGCACACTGCAGTTTTTGC-3’ 
C951S forward primer: 
5’-GAAAACAAAGCACTGCAAAAGAAGAGTGCCGACTATCAAATAAATGGTG-3’ 
C951S reverse primer: 
5’-CACCATTTATTTGATAGTCGGCACTCTTCTTTTGCAGTGCTTTGTTTTC-3’ 
 
 
Template plasmid was eliminated by adding 20 U of DpnI restriction enzyme 
(New England Biolabs, USA) and incubating at 37°C for 1 hr. Success of the DNA 
 11 
 
amplification was checked using an ethidium bromide stained agarose gel, visualized by 
UV exposure. The plasmid product was used to transform BL21 (DH5α) cells and a 
single-colony plasmid was isolated. Presence of the mutation within the isolated plasmid 
was verified by DNA sequencing. The mutated plasmid was used to transform E. coli 
BL21 (DE3) heat-shock competent cells, which were then plated on LB agar plates 
containing 100 mg/L ampicillin. 
 
Small scale protein expression test of MDA5 
For each construct, one colony was picked from the corresponding agar plate and 
used to inoculate 5 mL of LB broth. Each cell culture was incubated at 37°C for 2-4 hr 
with 250 rpm shaking until the OD600 reached approximately 0.8. To induce expression, 
1 mM IPTG was introduced to 1 mL of the culture. Both the induced and non-induced 
cultures were incubated at 37°C for 3 hr. A 2 mL aliquot of the non-induced culture was 
allowed to continue incubation for an additional 2 hr, at which time it was stored at -
80°C in 16% glycerol as a stock culture for use in the large scale expression. The 1 mL 
induced culture and 1 ml of the non-induced culture were harvested by centrifugation at 
15,000 g for 1 min and their supernatants were discarded. The cell pellets were 
resuspended in 50 μl of lysozyme (0.2 mg/ml) and 1 ul of DNase (1 mg/ml). The cells 
were lysed by first flash freezing in N2(l), then incubating at 37°C for 5 min, and then 
repeating this freeze-thaw cycle four more times. After lysis, the soluble and insoluble 
fractions were separated by centrifugation at 15,000 g for 1 min.  Both fractions were 
then analyzed by SDS-PAGE using either an 18% gel (MDA5 RD only) or a 10% gel 
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(all other constructs) to determine the feasibility of expressing the respective protein in 
E. coli. For all SDS-PAGE gels, the Dual Color Protein Plus molecular weight ladder 
from Bio-Rad (USA) was used to determine the size of the expressed proteins. 
 
Large scale MDA5 expression and purification 
Large scale expression of the MDA5 constructs was done by first preparing a 
starter culture: 25-100 mL of LB broth with antibiotic (50 mg/L kanamycin or 100 
mg/mL ampicillin). For each 25 mL of starter culture, a total of 25 μL of -80°C stock 
culture was used to inoculate. The starter culture was allowed to incubate at 37°C for 3 
hr with shaking at 250 rpm. The starter culture was then used to inoculate a large scale 
culture, inoculating 1 L of LB broth with antibiotic (50 mg/L kanamycin or 100 mg/mL 
ampicillin) for each 25 mL of starter culture. Larger culture volumes were used in the 
case of low protein expression or solubility. For the expression of the MDA5 RD and 
MDA5 HDRD constructs, 100 mM ZnSO4 was added to the expression cultures after 
inoculation. This concentration of Zn2+ is necessary to allow for the successful formation 
of the zinc-finger motif in the MDA5 RD. Once the culture reached a cell density of 
OD600=0.8, the cultures were cooled to 15°C and then protein expression was induced by 
adding 400 μM IPTG. The induced culture was then incubated at 15°C for 16-20 hr.  
The expression cultures were harvested by centrifugation at 4,000 g for 10 min. 
at 4°C, discarding the supernatant. The cell pellet was resuspended in 4°C lysis buffer 
(150 mL of 300 mM NaCl, 50 mM Tris, pH 8.0). The cells were lysed by sonication in 
an ice water bath for 10 min, using a 0.5 sec on/0.5 sec off pulse. Insoluble proteins and 
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cellular debris were removed through a two-step centrifugation process at 4°C: 8,000 g 
for 10 min. and then 16,000 g for 10 min. The insoluble pellets were discarded and the 
supernatant was used for subsequent purification. 
The expressed MDA5 constructs were purified from the supernatant by 6xHis tag 
nickel affinity. The supernatant was loaded onto a Ni2+ Sepharose High Performance 
HisTrap column (GE Healthcare, USA) pre-equilibrated with 4°C lysis buffer. Non-
specifically bound proteins were washed from the column using wash buffer (300 mL of 
25 mM imidazole, 500 mM NaCl, 20 mM Tris, pH 7.5). The wash buffer was pre-cooled 
to 4°C. The high salt (500 mM) of this washing step also served to disrupt any 
contaminating protein or RNA complexes that may have formed during expression and 
subsequent cell lysis. The purified MDA5 protein was then eluted from the column using 
elution buffer (250 mM imidazole, 150 mM NaCl, 20 mM Tris, pH 7.5). The elution 
buffer was also pre-cooled to 4°C. Eluted fractions were collected in 5 mL increments 
and the presence of protein was detected by Bradford assay. The highest concentration 
fractions were pooled and final protein concentrations were measured by A280 and 
Bradford assay. To improve protein stability, 5 mM DTT was added to the purified 
protein samples after A280 measurements were completed. 
To further purify the MDA5 RD construct, the eluted protein sample was 
concentrated to 2 ml by an Amicon Ultra-4 10 kD centrifugal filter (Millipore) at 4000 g 
at 4°C. The sample was then injected onto a Superdex75 16/60 HiLoad SEC column 
(Amersham Biosciences) pre-equilibrated with running buffer (150 mM NaCl, 20 mM 
Tris, pH 7.5). The sample was resolved at 1 ml/min using running buffer at a flow rate of 
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1.0 mL/min. and a maximum pressure of 0.35 MPa. The purified MDA5 RD protein was 
collected, brought to 5 mM DTT, and then placed immediately on ice before subsequent 
experimentation. 
For the MDA5 HD construct, the SUMO tag was cleaved from the HisTrap-
purified protein sample with the addition of 0.5 μM SUMO protease. Digestion was 
performed at 22°C for 1 hr. The digested sample was then further purified by SEC. The 
sample was concentrated to 2 mL by an Amicon Ultra-4 30 kD centrifugal filter 
(Millipore). The concentrated sample was injected onto and purified by the Superdex75 
16/60 HiLoad SEC column. However, the MDA5 HDRD constructs were not further 
purified after the HisTrap purification until after they were prepared as protein-dsRNA 
complexes. 
 
RNA preparation and purification 
RNA was synthesized as blunt-end single-strand oligos by Integrated DNA 
Technologies (IDT, USA). Oligos were designed as GC-rich sequences of the form 
GG[CG]NCC, with a total length of 10, 12, 14, or 16 bp. An additional pair of 14 bp 
sequences was designed with an AUAU sequence at either the 3’ end (designated as 14 
bp 3’ overhang) or the 5’ end (designated as 14 bp 5’ overhang). Each RNA sample was 
suspended in running buffer to a concentration of 1 mM ssRNA. The diluted ssRNA was 
then annealed to dsRNA by placing the sample in a 95°C water bath and then 
immediately cooling to 22°C over 1 hr. Within this document, all dsRNA is assumed to 
be IDT-synthesized, blunt-ended dsRNA, unless otherwise mentioned. 
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RNA synthesized by in vitro reverse transcription was also used. The in-house 
RNA was 12 or 14 bp in length and contained a triphosphate at the 5’ end. Removal of 
this cap through dephosphorylation was performed by incubation overnight at 37°C with 
calf intestinal phosphatase (CIP). Hereafter, in vitro transcribed dsRNA will be referred 
to as “IVT dsRNA”. 
 
MDA5 protein/RNA complex preparation and purification 
Two complex forms were prepared: MDA5 RD-dsRNA and MDA5 HDRDΔCL-
dsRNA. The MDA5 RD-dsRNA complexes were prepared by mixing the purified 
MDA5 RD protein in a 3:1 molar ratio with varied lengths of dsRNA. The RNA lengths 
used for each MDA5 RD-dsRNA complex included 10 bp, 12 bp, and 14 bp dsRNA. 
The complex was allowed to equilibrate on ice at 4°C for 30 min., after which the 
complex was analyzed by SEC using a Superdex200 10/30 SEC column (GE Life 
Sciences), pre-equilibrated with running buffer. A 100 μL aliquot was injected onto the 
column and the sample was resolved using running buffer at 0.4 mL/min. and a 
maximum pressure of 0.70 MPa. For this and all other SEC, relative protein and RNA 
concentrations were detected by in-line UV absorbance. 
The stable complex forms were concentrated to 2 mL using an Amicon Ultra-4 
10 kD centrifugal filter at 4000 g at 4℃. Purification of the MDA5 RD-dsRNA complex 
from unbound MDA5 RD was performed by loading the complex sample onto a HiLoad 
Superdex75 16/60 SEC column, pre-equilibrated with running buffer. The injected 
sample was resolved with running buffer at 1.0 mL/min. and a maximum pressure of 
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0.35 MPa. 1.5 mL fractions of the highest purity were pooled and 5 mM DTT was added 
to stabilize the sample. The concentration of the complex after purification was 
measured by Bradford assay. 
The MDA5 HDRDΔCL protein (purified by HisTrap) was mixed with 12, 14, or 
16 bp dsRNA at a 1.5:1 molar ratio. After dsRNA was added to the protein, the SUMO 
tag was removed by the addition of 0.5 μM SUMO protease. Digestion by SUMO 
protease and the formation of the complex occurred during incubation on ice at 4°C for 
16 hr. The sample was then brought to 1% PMSF and concentrated to 2 mL by an 
Amicon Ultra-4 30 kD centrifugal filter. The complex was then purified from unbound 
dsRNA by injecting the sample onto a HiLoad Superdex200 16/60 SEC column, pre-
equilibrated with running buffer. The sample was resolved with running buffer at 1.0 
mL/min. and a maximum pressure of 0.35 MPa. 
 
Binding and stoichiometry assays by SEC 
The complex stoichiometry of MDA5 RD (WT or C915S/C951S) and dsRNA 
was analyzed using a 1-4 protein:1 dsRNA molar ratio. After the protein and dsRNA 
were mixed at the indicated molar ratio, the sample was allowed to equilibrate on ice at 
4°C for 30 min. SEC analysis was performed by injecting a 100 μL sample onto a 
Superdex200 10/30 SEC column, pre-equilibrated with running buffer. The sample was 
resolved using running buffer at 0.4 mL/min. and a maximum pressure of 0.70 MPa. 
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MDA5 binding and stoichiometry by EMSA 
 For analyses of binding by EMSA, the concentration of dsRNA was maintained 
at ~5 μM with the protein maintained at 50 μM. For the stoichiometry analyses by 
EMSA, the molar ratio was 1-10 protein:1 dsRNA. In most cases a protein-only control 
and a nucleotide-only control were included for comparison. For analyses involving 
MDA5 HD and HDRD constructs the complex samples were equilibrated on ice for 12 
hours before analyses. For analyses involving the MDA5 RD construct, the complex 
samples were equilibrated on ice for 30 min. before analysis. The non-denaturing 
polyacrylamide gel used for EMSA was prepared by mixing 1.6 mL of 40% acrylamide 
and bis N,N'-Methylene-bis-acrylamide (29:1 acrylamide:bis ratio, Bio-Rad, USA) with 
0.8 mL of 10x Tris-boric acid buffer (890 mM Tris, 890 mM boric acid) to a final 
volume of 7.1 mL. To polymerize the gel, 80 μL of 10% ammonium persulfate and 10 
μL of TEMED were added. Samples were loaded and resolved at 150 V for 45 min. The 
gel was stained by ethidium bromide and exposed to UV to visualize the dsRNA. 
  
Crystallization, data collection and processing 
The purified complexes of MDA5 RD C915S/C951S and 10, 12, or 14 bp 
dsRNA were concentrated to 25 mg/mL, measured by Bradford assay. The purified 
complexes of MDA5 HDRDΔCL and 12, 14, or 16 bp dsRNA were concentrated to 10 
mg/mL, measured by Bradford assay. For the MDA5 HDRDΔCL 2 mM of a non-
hydrolyzable ATP analogue, AMP-PNP, was added. Crystallization screening for all 
complexes was performed by the hanging-drop method, using 2 μL of complex sample 
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and 2 μL of screening condition over a reservoir of 0.5 mL mother liquor. The screens 
were set up and incubated for at least 5 days in a temperature-controlled environment at 
either 4°C or 16°C. The screening conditions were obtained as kits from Hampton 
Research, Inc. (USA): Index, Crystal Screen, Crystal Screen 2, and PEGRx 1. 
The MDA5 RD C915S/C951S and 12 bp dsRNA complex was crystallized in 
17.5% PEG 3350, 0.1 M succinic acid, pH 7.0 and grown for 15 days at 4°C. The 
complex crystal was transferred stepwise into a cryobuffer containing 30% PEG 400, 
17.5% PEG 3350, 0.1 M succinic acid, pH 7.0. The crystal was then mounted in a cryo 
loop and flash-frozen in N2(l). Diffraction data were collected at 100 K at the Lawrence 
Berkeley National Labs Advanced Light Source using a 3 x 3 CCD array at a 
wavelength of 1.28254 Å. The wavelength was chosen to permit single wavelength 
anomalous diffraction (SAD) using the Zn heavy atom of the MDA5 RD zinc-finger 
motif. The crystal was rotated through 120° with 1° oscillations and 5 seconds exposure 
per frame. Data were processed using the HKL2000 package [22]. Attempts at resolving 
the phasing problem by SAD and molecular replacement (MR) were attempted using the 
Phenix package. [23] 
 
Results 
MDA5 mutation, expression, and purification 
Initial expression of the MDA5 RD construct (15 kD) was performed in a 2 L 
culture and purified as described. The HisTrap purification process was analyzed by an 
18% SDS-PAGE before purifying by SEC. (Fig. 2A) The UV chromatogram for the wild 
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 type (WT) MDA5 RD showed the presence of an unknown secondary peak that 
resolved to a position corresponding to the molecular weight of an MDA5 RD dimer. 
(Fig. 2C) This dimer formation was possibly the result of two surface cysteines forming 
a disulfide bond, and so site-directed mutagenesis was performed. Two surface cysteine 
residues candidates were identified using the MDA5 RD crystal structure and mutated to 
serine residues (PDB 3GA3; Fig. 2B). [24] The new MDA5 RD C915S/C951S protein 
Fig. 2: MDA5 RD expression. A: SDS-PAGE analyses of HisTrap purification of the wild type 
and C915S/C951S mutant proteins; L – protein ladder; lanes 1,2 – insoluble fraction; lane 3 –
unpurified soluble fraction; lane 4 – wash fraction; lane 5 – elute. B: MDA5 RD structure (PDB 
3GA3) showing location of the mutated cysteine residues as spheres; arrow indicates RNA 
binding surface. C: UV chromatograms of SEC purification; arrow indicates position of the 
MDA5 RD WT dimer peak. 
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was expressed in the same manner as the WT (Fig. 2A). The contaminating dimer peak 
was effectively eliminated as shown by the UV chromatogram of the gel purification. 
(Fig. 2C) This mutant had an expression and yield of protein comparative to the WT. 
The MDA5 HD construct was expressed as a SUMO-tagged protein in a 2 L 
culture and purified as described. The HisTrap purification process was analyzed by a 
10% SDS-PAGE gel owing to the larger size of the protein (68 kD without the SUMO 
tag). A significant portion of the expressed protein was found in the insoluble pellet, 
despite the presence of the soluble SUMO tag. (Fig. 3A) SUMO protease digestion of 
the soluble HisTrap-purified MDA5 HD was performed at 22°C for 1 hr. Purification by 
HisTrap, digestion by SUMO protease, and purification by SEC (Fig. 3B)  were all 
completed the same day that the expression culture was harvested. The purified protein 
was stable and remained soluble for several days on ice in the presence of 5 mM DTT. 
Fig. 3: MDA5 HD expression. A: SDS-PAGE of HisTrap purification and SUMO protease 
digestion; L – protein ladder; lane 1,2 – insoluble fraction; lane 3 – unpurified soluble fraction; 
lane 4 – wash fraction; lane 5 – elute; lane 6 – SUMO-tagged MDA5 HD; lane 7 – MDA5 HD 
after digestion by SUMO protease. B: UV chromatogram of MDA5 HD purification by SEC. 
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The MDA5 HDRD constructs (each ~81-84 kD without SUMO tag) were 
expressed as SUMO-tagged proteins. The WT, ΔC, ΔL and ΔCL constructs were each 
purified by HisTrap, digested by SUMO protease, and then analyzed by 10% SDS-
PAGE gel. (Fig. 4) The construct with the highest purity and stability was determined to 
be the ΔCL truncation. Initial purification of the protein by SEC was problematic as the 
MDA5 HDRDΔCL protein would aggregate and degrade within a few hours after His-
Trap purification unless the sample was stabilized by binding to RNA prior to digestion 
by SUMO protease. In addition, the protein also suffered from proteolytic degradation 
prior to purification by SEC. To mitigate this, 1% PMSF, a serine protease inhibitor, was 
added immediately after SUMO protease digestion. 
 
 
 
Fig. 4: MDA5 HDRD expression. SDS-PAGE of SUMO digestion of MDA5 HDRD 
constructs and HisTrap purification of MDA5 HDRDΔCL. For all constructs: L – protein 
ladder; T – SUMO-tagged protein; -T – protein after removal of SUMO tag. For ΔCL 
construct: 1 – insoluble fraction; 2 – soluble fraction; 3 – wash fraction. 
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Stoichiometry of MDA5 to dsRNA 
As the RIG-I and LGP2 RD protein complexes with dsRNA have a stoichiometry 
of 2 protein:1 dsRNA, it was hypothesized that the same would be true of the MDA5 
RD. [11, 14] Binding analyses of the MDA5 RD WT protein with 14 bp dsRNA were 
performed by SEC using a molar ratio of 1-4 protein:1 dsRNA. (Fig. 5) The UV 
chromatograms show that the binding stoichiometry is approximately 2 protein:1 
dsRNA. When the analyses were repeated with the MDA5 RD C915S/C951S mutant, 
the binding stoichiometry was similar, but the binding stability was greatly increased. 
(Fig. 6) This binding change may be due to the MDA5 RD no longer forming a stable 
dimer, or it may be due to the cysteine mutant having an influence on the binding site. 
Fig. 5: MDA5 RD WT binding to 14 bp blunt dsRNA. With the exception of the protein-only 
control, 30 μM dsRNA was constant for each sample. The protein-only control contained 60 μM 
MDA5. The protein:dsRNA molar ratio is noted for each analyzed complex sample. 
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Cys951 is in close proximity to the RNA binding surface (Fig. 2B) and may be 
responsible for this effect. 
 
 
For the MDA5 HDRD constructs, EMSA was used instead of SEC analysis to 
analyzed stoichiometry. (Fig. 7) Due to protein instability, the SUMO tag was not 
removed from MDA5 HDRD prior to analysis. Based upon the data, the point at which 
all of the RNA is bound to the MDA5 protein is between 5-10 protein:1 dsRNA. This 
Fig. 6: MDA5 RD C915S/C951S binding to 14 bp blunt dsRNA. UV chromatograms 
generated from SEC of MDA5 RD C915S/C951S with 14 bp dsRNA. With the exception of the 
protein-only control, 50 μM dsRNA was constant for each sample. The protein-only control 
contained 100 μM MDA5. The protein:dsRNA molar ratios are noted for each analyzed 
complex sample. 
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high ratio is supported by Piesley et al. who showed that at low concentrations MDA5 
has a low affinity for short dsRNA. [25] In addition, the EMSA shows that the protein- 
 
only control samples contain some nucleic acid contaminant. This is possibly RNA from 
E. coli that was bound to the MDA5 protein during expression or lysis and not removed 
by the 0.5 M NaCl wash of the HisTrap purification. As a result, this data was only used 
to determine the existence of RNA binding, not the stoichiometry of the complex. 
Fig. 7: EMSA of MDA5 HDRD constructs complexed with 12 bp blunt dsRNA. RNA and 
protein lanes are controls. All listed molar ratios are in the format protein:dsRNA. 
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MDA5 binding to dsRNA 
Analysis of the mechanism of MDA5 RD binding to dsRNA was examined. The 
binding of MDA5 RD (WT and C915S/C951S mutant) to dsRNA with a 5’ overhang, a 
3’ overhang, a 5’ triphosphate group, or a blunt end were tested by EMSA. (Fig. 8) This 
analysis was also performed by SEC for the C915S/C951S mutant. (Fig. 9) As expected, 
the tests showed that the strongest binding occurred with blunt dsRNA. Binding was 
seen with the 5’ triphosphate dsRNA, which was confirmed by SEC. Binding was also 
seen with the 3’ overhang dsRNA, but no binding was seen by SEC analysis. The 5’ 
overhang dsRNA also showed binding with MDA5 RD by EMSA, but as with the 3’ 
overhang, no binding of this oligo was seen using SEC. The C915S/C951S mutant 
shows a different behavior on the EMSA compared to the WT. Complex formation with
Fig. 8: Effect of C915S/C951S mutation on MDA5 RD ligand recognition. EMSA of four 
forms of 14 bp dsRNA complexed with MDA5 RD WT and MDA5 RD C915S/C951S 
constructs. WT and mutant headers designate the WT complex and C915S/C951S complex 
respectively. Complexes are formed from a molar ratio of 10 protein:1 dsRNA. 
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 the blunt-end, 5’ overhang, and 5’ triphosphate forms of dsRNA is more distinct for the 
C915S/C951S mutant compared to the WT. This difference was also seen by SEC 
during the prior stoichiometry experiments. 
The SEC method relies upon separation by high pressure flow from a low 
volume into a high volume matrix composed of porous beads using a buffer composed 
of moderate salinity and pH (150 mM NaCl, 20 mM Tris, pH 7.5). The EMSA method 
Fig. 9: Effect of dsRNA ends on the binding stability of MDA5 RD C915S/C951S. UV 
chromatogram results of SEC on MDA5 RD C915S/C951S protein mixed with alternate forms 
of dsRNA. Light line – dsRNA control; dashed line – protein control; solid dark line – 2:1 
complex.  
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instead applies a voltage gradient to draw the sample through a porous gel and contains 
lower salinity (89 mM Tris, 89 mM boric acid). The relative concentration of the 
complex sample within the EMSA gel (0.45 μM) is also higher than within the SEC 
matrix (0.16 μM). The higher salinity of the SEC buffer coupled with the lower 
concentration of complex may impair the binding of MDA5 RD with the 3’ and 5’ 
overhang dsRNA. 
The binding of 5’ triphosphate dsRNA to MDA5 was further investigated using 
the HDRDΔCL construct and the RD C915S/C951S mutant. For this experiment, the 
SUMO tag was not removed from the HDRDΔCL. A sample of 12 bp IVT dsRNA and 
14 bp IVT dsRNA were each dephosphorylated by CIP. An EMSA was then used to test 
and compare the binding capacity of MDA5 HDRDΔCL to 12 bp dsRNA with and 
without a 5’ triphosphate cap. (Fig. 10A) Concentrations of RNA were constant for each 
lane. The 5’ triphosphate group of the IVT dsRNA appears to inhibit binding by the 
HDRDΔCL protein, but after CIP-digestion the binding behavior resembled that of blunt 
dsRNA. Unfortunately, all lanes contained several contaminating bands, possibly the 
result of contaminating bacterial RNA, making it difficult to make a positive conclusion. 
The impact of the 5’ triphosphate group on dsRNA binding with the MDA5 RD 
C915S/C951S construct was analyzed using SEC. (Fig. 10B and 10C) The 14 bp blunt 
dsRNA complex resolved at 16.1 mL while the RNA-only control resolved at 17.8 mL. 
The complex using CIP-digested 14 bp IVT dsRNA resolved at 16.5 mL, while the 
RNA-only control resolved at 17.3 mL. With uncut 14 bp IVT dsRNA, the complex 
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resolved at 16.8 mL but the RNA-only control resolved at 17.0 mL. The significant 
difference in resolution positions for the uncut IVT dsRNA and the CIP-digested sample 
suggest that the 5’ triphosphate group was successfully removed.It is clear from the 
chromatogram comparison that the presence of the 5’ triphosphate impairs binding of the 
MDA5 RD C915S/C951S complex with dsRNA. Unfortunately, complexes prepared 
using this relatively less expensive RNA source would not crystallize, suggesting that 
crystallization of this complex is more sensitive than first suspected. 
Fig. 10: MDA5 binding to IVT dsRNA before and after CIP digestion. A: UV chromatogram 
of SEC analysis of MDA5 RD C915S/C951S in complex with 14 bp blunt dsRNA. B: UV 
chromatogram of SEC analysis of MDA5 RD C915S/C951S in complex with 14 bp IVT dsRNA
before and after digestion by CIP. C: EMSA of MDA5 HDRDΔCL in complex with 12 bp 
dsRNA; lane 1 – blunt dsRNA, lane 2 – IVT dsRNA with an undigested 5’ triphosphate group, 
lane 3 – IVT dsRNA after removal of the 5’ triphosphate group by CIP digestion. Arrow 
indicates unbound dsRNA. 
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Binding analysis was also performed with the MDA5 HD construct to see if the 
HD was directly involved with RNA binding. As before, the RNA used was 12 bp 
dsRNA, an oligo known to bind strongly to both the RD and HDRD constructs. 
However, no binding of dsRNA with the MDA5 HD construct was seen by either EMSA 
or SEC analysis. (Fig. 11) 
It is known that stimulation and binding of the full length MDA5 protein to 
dsRNA in vivo is independent of the presence of a 5’ triphosphate end. Binding behavior 
is instead dependent upon the length of the foreign RNA. [26] Based upon the data 
shown here, it appears that the MDA5 protein directly interacts with the 5’ end of 
dsRNA even if the length of the RNA is below the 0.5-7 kb stability threshold. [17] The 
data shows that phosphate groups impair MDA5 binding when there is interaction with 
Fig. 11: MDA5 HD binding to 12 bp dsRNA. A: EMSA of MDA5 HD in complex with 12 bp 
dsRNA; molar ratios are in the format protein:dsRNA. B: UV chromatogram of SEC analysis of 
MDA5 HD C915S/C951S in complex with 12 bp dsRNA. No interaction of MDA5 HD with 
dsRNA was observed in either analysis. 
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 the 5’ end of dsRNA. In the case of dsRNA with 5’ overhangs or 3’ overhangs, ligand 
concentration and ionic strength of the solution may have an effect on whether the 
complex can readily form. 
 
MDA5 HDRD crystal screening 
Crystallization screening of the complex of MDA5 HDRD with dsRNA was 
performed using 12 bp dsRNA and the ΔCL construct. The complex was prepared by 
mixing the expressed SUMO-tagged protein with 12 bp dsRNA in a 1.5 protein:1 
dsRNA molar ratio. The complex mixture was incubated overnight at 4°C on ice after 
adding 5 mM DTT and 0.5 μM SUMO protease. The sample was tested by 10% SDS-
PAGE to confirm SUMO protease digestion. Immediately before the sample was 
concentrated for SEC purification, 1% PMSF was added to the sample. The complex 
was purified by SEC and the purified complex was collected as 1.5 mL fractions. These 
fractions were examined by 10% SDS-PAGE and denaturing polyacrylamide gel. Both 
the MDA5 HDRDΔCL and the 12 bp dsRNA were verified to be present in the complex 
peak. (Fig. 12) The purified complex was concentrated to 10 mg/mL for crystallization 
screening at 4°C. 
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To optimize the crystallization, AMP-PMP, a non-hydrolyzable ATP analogue, 
was added at 2 mM. It was hypothesized that the same inhibitory effect of this molecule 
that allowed crystallization of the RIG-I HDRD complex with dsRNA would provide the 
same benefit for crystallization of the MDA5 HDRDΔCL complex with dsRNA. No 
crystals formed during the initial screen at 4°C. Additional screens at 16°C produced 
similar results. MDA5 HDRDΔCL-dsRNA complexes using 14 bp dsRNA and 16 bp 
dsRNA were also screened, but no crystallization occurred. 
 
 
Fig. 12: Purification of MDA5 HDRDΔCL complex with 12 bp dsRNA. A: UV 
chromatogram of purification by SEC; ranges listed above red boxes correspond to fractions 
analyzed in B and C; fractions 1-5 are the complex, 6-9 is unbound dsRNA. B: 10% SDS-
PAGE analysis of fractions; L – protein ladder; arrow indicates the MDA5 HDRDΔCL protein. 
C: denaturing polyacrylamide gel analysis of fractions, visualized by UV. 
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MDA5 RD crystallization optimization, diffraction, and data analysis 
A complex sample was prepared using the MDA5 RD C915S/C951S construct 
and 14 bp dsRNA. The protein and dsRNA were mixed in a 3 protein:1 dsRNA molar 
ratio and allowed to incubate on ice for 30 min. The complex was then purified by SEC 
to remove any unbound protein. (Fig. 13A) The purified complex was concentrated to 25 
mg/mL and used for crystallization screening. The screens were performed by the 
hanging-drop method at 4°C. Needle-like crystals formed in 22% (w/v) polyacrylic acid 
Na salt, 5100, 20 mM MgCl2, 0.1 M HEPES, pH 7.5. The crystals were not discrete, and 
so optimization was performed using a lower range of precipitant. This process produced 
single crystals, but the optimized crystals (Fig. 13B) did not grow large enough to be 
usable for diffraction. To find an alternate crystallization condition potentially more 
Fig. 13: Purification and crystallization of MDA5 RD C915S/C951S with dsRNA. A: UV 
chromatogram of purification by SEC of MDA5 RD C915S/C951S complexed with three 
lengths of blunt dsRNA – 10 bp, 12 bp, and 14 bp; arrows indicate the positions of the 
complex peaks. B: Optimized crystals of the MDA5 RD C915S/C951S and 14 bp dsRNA 
complex. Scale is 63 μM per unit. 
 33 
 
receptive to optimization, shorter dsRNA oligos were used for complex formation: 10 bp 
and 12 bp dsRNA. These complex samples were prepared and purified in the same 
manner as the 14 bp dsRNA complex. (Fig. 13A) 
Screens using the purified MDA5 RD C915S/C951S and 10 bp dsRNA complex 
produced three crystals (Fig. 14), each large enough to be used in X-ray diffraction 
analysis. A 1.3 mm x 2.8 mm x 0.7 mm crystal formed in 45% MPD, 0.2 M Ammonium 
acetate, 0.1 M BIS-Tris, pH 5.5. A separate 0.4 mm x 2.0 mm x 0.6 mm crystal formed 
in 30% PEG 400, 0.2 M Sodium citrate tribasic dihydrate, 0.1 M Tris, pH 8.5. A third 
2.6 mm x 2.4 mm x 0.6 mm crystal formed in 0.2 M NaCl, 10% PEG 6000. All of the 
 
crystals formed after 5 days incubation at 4°C. The crystals were washed in their 
respective original conditions and then flash frozen in N2(l). The crystals were analyzed 
at 180 K by X-ray diffraction using a Raxis IV++ detector mounted on a Rigaku 
Micromax-007HF generator. The collected data were processed and it was determined 
Fig. 14: RNA crystals formed from a 10 bp dsRNA complex sample. A: crystal formed in 
45% v/v MPD, 0.2 M Ammonium acetate, 0.1 M BIS-Tris, pH 5.5. B: crystal formed in 30% 
v/v PEG 400, 0.2 M Sodium citrate tribasic dihydrate, 0.1 M Tris, pH 8.5. C: crystal formed 
in 0.2 M NaCl, 10% PEG 6000. Scale shown is 63 μM per unit. 
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that in all three cases the crystals were composed exclusively of dsRNA and did not 
contain any of the MDA5 RD C915S/C951S protein. 
The purified MDA5 RD C915S/C951S and 12 bp dsRNA complex sample was 
screened in the same manner as the 10 bp and 14 bp dsRNA complexes. Crystals formed 
in 15% PEG 3350, 0.1 M succinic acid, pH 7.0 at 4°C after 6 days. (Fig. 15A) To verify 
the presence of protein and RNA in the crystal, a sample crystal was washed in its 
original condition and then analyzed by both 18% SDS-PAGE and denaturing 
polyacrylamide gel. Visualization of the gels by Coomassie blue and ethidium bromide 
staining revealed the presence of both protein and RNA in the washed crystal. 
Optimization of this crystallization condition produced a crystal suitable for data 
collection. The crystal was grown in 17.5% PEG 3350, 0.1 M succinic acid, pH 7.0 at 
Fig. 15: Crystals formed from MDA5 RD C915S/C951S in complex with 12 bp dsRNA. 
A: crystal formed in the initial optimization screen. B: optimized crystal. Scale shown is 63 
μM per unit. 
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4°C for 15 days to a final size of 0.7 mm x 1.7 mm x 0.4 mm. (Fig. 15B) The crystal was 
transferred stepwise to a cryobuffer containing the original condition plus 30% PEG 400. 
The crystal was then flash frozen in N2(l) and analyzed at the Lawrence Berkeley 
National Labs synchrotron. The wavelength chosen for diffraction was 1.28255 Å. This 
wavelength was determined by fluorescence scanning to have the highest signal-to-noise 
ratio for Zn-SAD. Diffraction data were collected and processed using the HKL2000 
package. 
The Phenix package was used to solve the phasing problem. [23] The crystal was 
determined to have severe pseudo merohedral twinning, which was the case for all of the 
crystals that were grown using this condition and analyzed by X-ray diffraction. This 
indicates that the twinning is likely an artifact of the crystal’s growth pattern and not the 
freezing process. The data was determined to have a 0.45 twin fraction using the –h, -k, 
+l law. In addition, the low overall signal strength of the Zn anomalous signal prevented 
resolution of the structure by SAD, and despite numerous attempts the phasing problem 
could not be resolved by MR. The statistics of the processed data are summarized in 
Table 3. 
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Table 3: Summary of diffraction data for MDA5 C915S/C951S with 12 bp dsRNA 
 
MDA5 C915S/C951S and 
12 bp dsRNA complex 
Wavelength (Å) 1.28255 
Resolution range (Å)         50.00-3.20 (3.26-3.20) 
Space group P31 or P32 
Unit cell parameters (Å)  a = b = 149.053, c = 73.428 
Total No. of reflections 853748 
No. of unique reflections 76923 
Completeness (%) 97.1 (88.9) 
Mean I/σ (I)  27 (1.73) 
Rsym
† (%) 9.4 (77.5) 
 
 
 
 
  
†Rsym = ∑h∑i |Ii,hkl – <Ihkl>|/∑hkl∑i |Ii,hkl|, where Ihkl,i is the 
intensity measured for a given reflection with Miller indices h, 
k, and l, and <Ihkl> is the mean intensity of that reflection. 
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CHAPTER III 
STRUCTURAL CHARACTERISTICS OF THE E.coli PROLINE PEPTIDASE PepQ 
 
Introduction 
Of all the 20 common amino acids, proline is the only residue with a structure 
that forms a cyclical bond with its amide backbone. This limits catalytic activity at the 
proline, as the backbone near the residue is less susceptible to proteolytic degradation 
than other residues. [27] As a result, many organisms have evolved multiple ways to 
specifically target and digest proline-containing peptides. [28] One pair of proline-
specific catalytic enzymes in particular in E. coli is PepP (proline aminopeptidase) and 
PepQ (prolidase). These proteins have a high sequence similarity to the Alteromonas sp. 
organophosphorus acid anhydrolase (OpaA), which has both proline dipeptidase activity 
and is capable of hydrolyzing toxic organophosphorus compounds found in nerve 
agents. PepQ in particular has 51% sequence identity to OpaA and was also found to 
have strong hydrolysis activity for organophosphorus compounds. [29] 
In solution, E. coli PepP has been characterized as forming a tetramer and 
hydrolyzes the peptide backbone just before the proline in the N-terminal motif NH2-
Xaa-Pro-Xaa-. In contrast, E. coli PepQ forms a dimer in solution and instead recognizes 
dipeptides with the motif NH2-Xaa-Pro-CO2H. [29] Of these two enzymes, the PepP 
structure (PDB ID: 1AZ9, 1JAW, 1M35) has already been determined. [30] 
Determination of the structure of PepQ would permit a comparison to PepP and similar 
homologues, and may elucidate why the oligomeric structure is different. 
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Specific aim: X-ray crystallography of PepQ  
Purified full length PepQ protein was screened in various crystallization 
conditions and then diffracted by the Raxis IV home source. Data were collected and the 
unrefined crystal structure was resolved. Analysis of the structure and comparison to the 
structures of two PepQ homologues (PepQ from Alteromonas macleodii (3RVA) and 
OpaA from Alteromonas sp. (3L24, 3L7G)) is in progress. 
 
Experimental Procedures 
Sample preparation and crystallization of PepQ 
A sample of the PepQ protein was provided by the Hays Rye laboratory in 5 mM 
DTT, 5 mM MgCl2, 50 mM Tris, pH 7.5. Crystallization screening conditions were 
obtained from Hampton Research (USA): Index, Crystal Screen, Crystal Screen 2, and 
PEGRx-1. The protein was screened by the hanging drop method at 6 and 12 mg/mL. 
Drops composed of 2 μL sample and 2 μL condition were allowed to crystallize at 4°C. 
Irregular plate-like crystals formed after 10 days in 20% PEG MME 5000, 0.1 M Bis-
Tris pH 6.5. Optimization of the crystals was performed and an optimized crystal was 
grown to 2.8 mm x 2.8 mm x 0.3 mm over 14 days. This crystal was transferred stepwise 
into a cryobuffer containing 30% PEG 400, 20% PEG MME 5000, 0.1 M Bis-Tris, pH 
6.5. The crystal was mounted on a cryoloop and then flash-frozen in N2(l). 
 
Data collection and structural analysis 
Diffraction data for the optimized PepQ crystal were collected using a Raxis 
IV++ detector mounted on a Rigaku Micromax-007HF generator at 120 K. The crystal 
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was rotated through a total of 180 frames with 1° oscillations and 5 minutes per frame. 
The collected data were then analyzed and processed by the HKL2000 package. [22] 
The phasing problem was resolved by MR using the Alteromonas macleodii OpaA 
protein structure (3RVA) as a base structure. MR and refinement were performed using 
the Phenix package. [23] 
 
Results 
PepQ crystallization and data collection 
The PepQ protein was provided by the Hays Rye laboratory at the Texas A&M 
University as a 12 mg/mL -80°C glycerol stock sample. To improve the crystallization 
potential of the protein sample, glycerol was removed prior to crystallization. An aliquot 
of the protein was diluted to 6 mg/mL and then both samples were crystallized as 
described. Protein crystals did not visibly form until at least 8 days of incubation at 4°C, 
Fig. 16: Optimized PepQ crystal. Crystal shown formed on day 10 and was harvested on 
day 15. Scale is 63 μM per unit. 
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but the crystal growth rate quickly plateaued, with crystals reaching their maximum size 
two weeks post-screening. 
 
 
The E. coli PepQ protein was experimentally determined by the Hays Rye 
laboratory to be inhibited by HEPES, and so the addition of HEPES was used as a part 
of the crystallization optimization process. The addition of HEPES to the crystallization 
conditions impeded the nucleation process, and no crystals formed. The optimal 
Table 4: Statistics of diffraction data and refinement of E. coli PepQ 
Data Collection Refinement 
Wavelength (Å) 1.54178 Rwork/Rfree
‡ (%) 20.1/25.7 
Resolution range (Å) 30.20-2.26 (2.34-2.26) Bond lengths (Å) 0.0160 
Space group P212121 Bond angles (°) 1.58 
Unit cell parameters (Å) 
a = 71.111, b = 95.682, 
c = 127.329 Ramachandran plot (%) 
Total No. of reflections 853748 Favored 96.81 
No. of unique reflections 76923 Allowed 2.62 
Completeness (%) 98.9 (97.5) Disallowed 0.57 
Mean I/σ (I) 14.7 (3.2)   
Rsym
† (%) 16.4 (64.0) 
†Rsym = ∑h∑i |Ii,hkl – <Ihkl>|/∑hkl∑i |Ii,hkl|, where Ihkl,i is the intensity measured for a given 
reflection with Miller indices h, k, and l, and <Ihkl> is the mean intensity of that reflection. 
‡Rwork =∑||Fo|-|Fc||/∑|Fo|, where Fo and Fc are the observed and calculated structure-factor 
amplitudes, respectively. Rfree was calculated as Rwork using a randomly selected subset (10%) 
of unique reflections not used for structure refinement. 
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condition was found to be 19% PEG MME 5000, 0.1 M Bis-Tris, pH 6.5. The optimized 
crystal (Fig. 16) was grown as described and prepared for X-ray diffraction. Data was 
collected as described.  
 
Data processing and structural analysis of PepQ 
The Alteromonas macleodii OpaA protein has a sequence identity to the E. coli 
PepQ protein of 51%. The crystal structure of OpaA (3RVA) was used to develop a 
model PDB for PepQ using SWISS-Model. [15, 16, 31] This model structure was then 
used to resolve the phasing problem by MR using the Phenix package. [23] The attempt 
was successful, and the unrefined structure is presented here. Statistics for the crystal 
structure are listed in Table 4. 
The E. coli PepQ structure (Fig. 17) shows high similarity to the structures of 
Altermonas macleodii OpaA (3RVA) and Altermonas sp. OpaA (3L24), with a an 
aligned monomer-monomer RMSD of 0.63 Å and 0.65 Å, respectively. The unrefined 
electron density map of E. coli PepQ shows density within the active sites (Fig. 18). The 
active sites of both the Altermonas macleodii OpaA and Altermonas sp. OpaA homologs 
contain a pair of divalent cations (Mn2+). It is likely that this electron density represents 
the expected pairs of divalent cations. 
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Of interest in this structure is that the dimer interface is explicitly characterized. 
The structure shows several key polar interactions that stabilize the symmetrical dimer 
interface: Asp45 with His346 and Arg370, Gln344 with Asp44 and the carbonyl of 
Leu43, and the carbonyl of Trp89 with the amide backbone of His228 and Leu227. The 
structure also shows three hydrophobic interfaces that lock the dimer in position (Fig. 
19): a symmetrical core and two pockets positioned adjacent to the active sites of the 
dimer. The Trp89 reside is notable in that its carbonyl interacts with the amide backbone 
of His228, which is positioned along the outer edge of the active site of PepQ. (Fig. 20) 
Fig. 17: PepQ crystal structure overview. The PepQ complete dimer with predicted 
divalent cation pairs placed as magenta spheres. 
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Fig. 18: PepQ active site. The active site of PepQ chain A and chain B showing interactions 
(black dashed lines) with divalent cation pair (purple spheres); the 2Fo-Fc (blue mesh) and 
Fo-Fc (orange mesh) are shown. 
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It may be that once the Trp89 is involved with the hydrophobic dimer interface, the 
carbonyl of Trp89 pulls the His228 residue away from the active site, helping to form 
the outer edge of the active site pocket. 
 
Further refinement of this protein structure will need to be performed to properly 
position the divalent cations. Also, the validity of the interactions shown here should be 
tested experimentally, especially in the case of Trp89. If the conformation of Trp89 and 
associated interaction with His226 is indeed essential for the formation of the active site, 
this would provide valuable insight into how the inactive PepQ monomer becomes an 
active dimer. 
 
Fig. 19: Hydrophobic regions of the PepQ dimer interface. A: Central core of the dimer 
interface showing the positions of Phe39 and Tyr48 from both chains. B: hydrophobic region 
positioned near the active site of one chain; a similar interaction is seen near the active site of 
the other chain. 
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Fig. 20: Trp89 involved in the activation of the PepQ dimer. The carbonyl of the chain A 
Trp89 helps position the chain B H228 by a carbonyl-amide interaction. 
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CHAPTER IV 
SUMMARY 
 
Within this publication, both H. sapiens MDA5 and E. coli PepQ were studied. 
Experiments involving various techniques were performed on MDA5 constructs 
expressed from E. coli, with mixed levels of success. It was determined that the MDA5 
Cys951 residue, localized on a flexible loop near the MDA5 RNA binding surface, has 
an influence upon the binding of short dsRNA. In addition, MDA5 binding to the 5’ end 
of dsRNA is impaired by the presence of a 5’ triphosphate group. The effect of 5’ 
overhangs and 3’ overhangs on the binding of MDA5 to dsRNA is unclear. The HD of 
MDA5 does not directly bind to RNA, but its influence on binding within the full length 
protein is likewise not certain. These results support the currently established data on 
this particular protein. 
Studies on PepQ were restricted to structural analysis by X-ray crystallography. 
The purified protein was crystallized, diffraction data was collected, and the structure 
was successfully solved as a dimer. The active site for each subunit was found to relate 
very closely with the structures of Altermonas macleodii OpaA (3RVA) and Altermonas 
sp. OpaA (3L24). Three regions along the dimer interface show symmetrical 
hydrophobic interactions that lock the dimer, with a potential point of influence on the 
active site of one subunit by the Trp89 of the other subunit. The information from this 
structure will be used to further explore the nature and functions of the proline 
peptidases of bacteria.  
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